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Abstract 
Background:  Patients with HIV exposed to the antiretroviral drug abacavir may have an increased 
risk of cardiovascular disease (CVD). There is concern that this association arises because of a 
channelling bias. Even if exposure is a risk, it is not clear how that risk changes as exposure 
cumulates. 
Methods:  We assess the effect of exposure to abacavir on the risk of CVD events in the Swiss HIV 
Cohort Study. We use a new marginal structural Cox model to estimate the effect of abacavir as a 
flexible function of past exposures while accounting for risk factors that potentially lie on a causal 
pathway between exposure to abacavir and CVD. 
Results:  11,856 patients were followed for a median of 6.6 years; 365 patients had a CVD event (4.6 
events per 1000 patient years). In a conventional Cox model, recent – but not cumulative – exposure 
to abacavir increased the risk of a CVD event. In the new marginal structural Cox model, continued 
exposure to abacavir during the past four years increased the risk of a CVD event (hazard ratio 2.06, 
95% confidence interval 1.43-2.98). The estimated function for the effect of past exposures suggests 
that exposure during the past 6 to 36 months caused the greatest increase in risk. 
Conclusions:  Abacavir increases the risk of a CVD event: the effect of exposure is not immediate, 
rather the risk increases as exposure cumulates over the past few years. This gradual increase in risk 
is not consistent with a rapidly acting mechanism, such as acute inflammation. 
  
Keywords: HIV, antiretroviral therapy, reverse transcriptase inhibitors, adverse effects, marginal 
structural models 
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1. Introduction 
In 2008, an analysis by the D:A:D collaboration of observational cohorts showed that recent exposure 
to the antiretroviral drug abacavir was associated with an increased risk of cardiovascular disease 
(CVD) events.
1
 Subsequent meta-analyses of randomised controlled trials failed to find evidence of 
this association.
2-5
 The D:A:D emphasised that stopping smoking would do more to reduce the risk of 
a heart attack than stopping abacavir and noted that the absolute risk of such events was low.
6
 
Nevertheless, their results caused an unprecedented change in prescribing behaviour.
7
 
Neither cumulative nor past exposure to abacavir seemed to increase the risk of these events 
1
 and 
the D:A:D collaboration observed that while current use was a risk, this risk appeared to reverse 
shortly after the use of abacavir ceased.
8
 These factors led the collaboration to suggest that a rapidly 
acting mechanism, such as vascular inflammation, could be responsible for the increase in risk. 
However subsequent biomarker studies proved inconclusive 
9-12
 and analyses of other observational 
cohorts led to inconsistent results.
9,10,13,14
 
There is also lingering concern that any association between abacavir and CVD could be an artefact of 
either ‘channelling bias’ or the failure to adjust for potential confounders such as renal function or 
injection drug use.
9
 Indeed patients at higher risk of CVD were more likely to receive abacavir 
1,15
 (a 
‘channelling bias’ 
16
 or ‘confounding by indication’ 
17
). The D:A:D did not adjust for time varying risk 
factors such as blood lipid levels and blood pressure because, if they lie on a causal pathway between 
exposure to abacavir and CVD, adjusting for them could ‘adjust away’ the effect of interest.
18
 This 
situation necessitates more complex methods of analysis; marginal structural modelling 
19
 in 
particular has been recommended.
18,20,21
 
In most analyses, it is not known how the effect of exposure to a drug cumulates over time. 
Assuming a simple relationship between exposure and outcome can erode the power to detect a 
relationship and give a misleading picture of how best to minimise the risk of an adverse event.
22
 We 
assess the effect of exposure to abacavir on the risk of CVD events in the Swiss HIV Cohort Study 
(SHSC). First we reproduce the D:A:D's analysis using SHCS data; then we consider the likely results 
had they used more complex statistical methods. We fit a new marginal structural model 
23
 to 
estimate the effect of abacavir as a flexible function of past exposures while accounting for risk 
factors that potentially lie on a causal pathway between exposure to abacavir and CVD. 
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2. Methods 
2.1. Patients 
The SHCS is a prospective cohort with continuing enrolment of HIV-infected adults.
24
 Since 1 April 
2000, a cardiovascular risk assessment has been part of follow up visits scheduled every six months 
at one of seven outpatient clinics or at the office of a collaborating physician. At each assessment, 
blood pressure, smoking status, weight and body fat loss or gain are recorded and a blood sample 
taken to measure blood lipids. In this study, we include all patients with at least one cardiovascular 
risk assessment. 
2.2. Outcome, covariate and exposure definitions 
We consider a composite outcome to maximise the number of suitable disease events. As in the 
D:A:D study,
1
 we define a CVD event as the first occurrence of either a myocardial infarction, an 
invasive cardiovascular procedure or a cardiovascular related death. Each myocardial infarction or 
invasive cardiovascular procedure was documented in a checking chart;
25
 since 2005, each death has 
been documented using a CoDe cause of death form.
26,27
 
As in the D:A:D study, each patient’s follow-up is divided into consecutive one-month periods in our 
analyses. To reproduce the D:A:D’s analysis, we adjust for the same covariates in our conventional 
multivariate models. Hence these models have time-fixed covariates for demographic characteristics 
(age, sex, likely transmission through injection drug use, Caucasian ethnicity) and CVD risk factors 
(family history of coronary heart disease, previous CVD event); and  time-varying covariates for CVD 
risk factors (smoking status and body mass index, updated each follow up visit), calendar year, and 
cumulative exposure to 15 other antiretroviral drugs (with a separate covariate for each drug 
updated each month).  
Time varying covariates identified by the D:A:D as potentially on a causal pathway between exposure 
to abacavir and CVD are not included in our conventional multivariate models but are accounted for 
in our marginal structural Cox models. These covariates are represented by separate indicators for 
hypertension, dyslipidaemia and diabetes (and in a sensitivity analysis, an indicator for chronic kidney 
disease); indicators for three Framingham risk score categories;
28
 and continuous measures of CD4 
cell count and log 10 HIV RNA (viral load). 
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When estimating the effect of abacavir as a flexible function of past exposures, exposure is 
represented by an indicator variable with value one if the patient was taking abacavir on the first day 
of the month. Other estimates of the effect of abacavir use exposure indicators and duration of 
exposure as at the first day of the month derived from the exact dates the patient started and 
stopped taking abacavir. 
2.3. Statistical Analyses 
We analyse time to a first CVD event using various forms of the Cox proportional hazard model. For 
each patient, follow up begins at their first CVD risk assessment. A patient with no CVD event during 
follow up is censored at a death unrelated to CVD, six months after their last CVD assessment if lost 
to follow up or at the end of the study (30 September 2012), whichever comes first. As in the D:A:D’s 
analyses, we assume that censoring is uninformative. 
2.4. Conventional modelling 
We fit three conventional Cox models; all adjust for the same covariates but the history of exposure 
to abacavir is represented in different ways. The first model reproduces an analysis reported by the 
D:A:D, with two time varying exposure variables: one for the total duration of past use (cumulative 
use), the other an indicator of any exposure within the previous six months (recent use). The other 
two conventional models use exposure variables suggested by the results of our cumulative exposure 
modelling. These results suggest that current exposure to abacavir might be protective and that 
exposure during the past 6 to 36 months causes the greatest increase in the risk of a CVD event. 
Hence the second model has three exposure variables: cumulative use as before, but with recent use 
partitioned into two indicators – use in the current month and use in the previous one to six months. 
The third model has exposure to abacavir represented by three variables – current use, use in the 
previous one to six months and the total duration of use over the past 7 to 36 months. 
2.5. Marginal structural modelling 
We also fit the models described above as marginal structural Cox models using stabilised inverse 
probability of treatment weights (Section 1, Supplemental Digital Content, 
http://links.lww.com/QAI/A680).  This process requires eight different logistic regression models in 
order to estimate the probability that in a given month a patient either starts treatment with 
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abacavir (if abacavir-naive) or continues treatment with abacavir (if already exposed) given the most 
recent values of confounding variables. The process also allows relationships between confounding 
variables and treatment to change after February 2008 because prescribing behaviour changed after 
the D:A:D’s results were published.
7,29
 
2.6. Cumulative exposure modelling 
We fit a new marginal structural model that estimates the effect of abacavir as a flexible function of 
past exposure while using the same inverse probability of treatment weights as above.
23
 Exposure to 
abacavir is defined as a weighted sum of use in each past month, with (exposure) weights found by 
estimating a cubic spline for the relative importance of exposure at different times in the past. We 
assume that exposure more than four years ago would have no effect on the current risk of a CVD 
event. We consider nine alternative weight functions (Section 2, Supplementary Digital Content, 
http://links.lww.com/QAI/A680): these differ in their degree of flexibility and in whether weights are 
forced to take zero value at both the beginning and end of the four year interval, or just at the end of 
four years, or can take values other than zero at all times. A zero weight at the beginning of the four 
year interval implies there is a lag between exposure and its effect on the current risk of an event. 
Having selected the best fitting weight function, we estimate a hazard ratio comparing two different 
treatment strategies – always exposed to abacavir over the entire four years versus never exposed 
over this period. 
2.7. Additional analyses 
We re-fit our weighted models with a time varying indicator of chronic kidney disease added to the 
covariates used to calculate inverse probability of treatment weights (Section 3, Supplemental Digital 
Content, http://links.lww.com/QAI/A680). This sensitivity analysis requires a truncated data set, 
limited to follow up after January 2002 when routine serum creatinine measurement began in the 
SHCS.
31
 We define chronic kidney disease as an estimated glomerular filtration rate (calculated using 
CKD-EPI equation 
32
) below 60 ml/min/1.73m
2
. 
In two unplanned sensitivity analyses, we re-fit models for abacavir after excluding patients infected 
with HIV through injection drug use and after excluding patients exposed to abacavir before their 
first cardiovascular risk assessment (Section 4, Supplemental Digital Content, 
http://links.lww.com/QAI/A680). The second of these analyses avoids a bias that would arise if 
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existing uses of abacavir were in a sense 'survivors' at low risk of CVD,
33
and its population of abacavir 
naive patients corresponds to the 'full population' used in a recent analysis by the NA-ACCORD.
34
 
We also carry out a set of analyses for two other antiretroviral drugs from the same drug class: 
didanosine and tenofovir (Sections 5 and 6, Supplemental Digital Content, 
http://links.lww.com/QAI/A680). The D:A:D collaboration found that recent exposure to didanosine 
was also associated with an increased risk of CVD events.
1
 Didanosine and abacavir are both 
guanosine analogues and hence might plausibly have similar effects. On the other hand tenofovir 
was not associated with an increased risk of CVD events, even though subject to the same 
channelling biases as abacavir.
35
 
3. Results 
3.1. Patients 
As at October 2012, 11,924 patients in the SHCS had at least one cardiovascular risk assessment and 
11,856 patients provided follow up with all covariates available. These 11,856 patients have been 
followed for a total of 80,004 patient years with a median follow up of 6.6 years (interquartile range, 
IQR, 2.8 to 11.6). Of these patients, 1549 were exposed to abacavir before assessments began, for a 
median duration of 0.7 years (IQR 0.2 to 1.4). During follow up, 4052 patients were exposed to 
abacavir, for a median duration of 3.4 years (IQR 1.3 to 6.0) and of these, 2297 stopped taking 
abacavir during follow up and 821 re-started again. During follow up, 365 patients had a CVD event 
(3.0%): of these, 195 had been exposed to abacavir (53%), for a median duration of 3.4 years (IQR 1.0 
to 5.9). Half of the CVD events included a myocardial infarction (Table 1). Of the 11,491 patients 
without a CVD event, 4312 had been exposed to abacavir (38%), for a median duration of 3.3 years 
(IQR 1.0 to 6.0). Patients who had a CVD event were older and more likely to be men, currently 
smoking, with a previous CVD event or a family history of such events (Table 1). They were also more 
likely to have diabetes, chronic kidney disease, hypertension, dyslipidaemia or lipodystrophy and had 
higher Framingham risk scores than those without an event. 
3.2. Conventional  and marginal structural modelling 
In our first conventional model (Table 2), the risk of a CVD event increased with recent exposure to 
abacavir (hazard ratio, HR, 1.50, 95% confidence interval (CI) 1.12 to 2.00) with weaker evidence of 
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an increase with greater cumulative exposure (HR 1.04, 95% CI 0.99 to 1.10, per year). These 
estimates are close to the equivalent estimates reported by the D:A:D (HR 1.63, 95% CI 1.30 to 2.04, 
for recent exposure and HR 1.03, 95% CI 0.96 to 1.10, per year for cumulative exposure 
1
). 
The other two conventional models use exposure variables suggested by the results of our 
cumulative exposure modelling (Table 2, footnotes). The first of these two models suggests that 
recent exposure in the past zero to six months can be partitioned into current exposure and recent 
exposure in the previous one to six months. In this second model, current exposure has a protective 
effect (HR 0.36, 95% CI 0.23 to 0.55) while recent exposure increases the risk of a CVD event (HR 
3.69, 95% CI 2.36 to 5.75) such that the mixing of current and recent exposure in the first model 
understates the risk posed by the latter. The third model suggests that cumulative exposure during 
the past seven months to three years (HR 1.25, 95% CI 1.04 to 1.51, per year) does indeed increase 
the risk of a CVD event, as predicted by our cumulative exposure modelling. 
Re-fitting these three models as marginal structural models led to very similar estimates (Table 2). 
3.3. Cumulative exposure modelling 
Of the nine exposure weight functions, the best fitting weight function had a single knot and weights 
of zero at both the beginning and end of the four year interval (Figure 1, left). This function implies 
that exposure to abacavir did not immediately increase the current risk of a CVD event; rather this 
risk reflects cumulating exposure to abacavir over the past 6sto 36 months. Of note, weight functions 
where the effect of current exposure could have a weight other than zero had negative weights for 
the earliest months of the interval suggesting that current exposure might have a protective effect 
(Section 2, Supplemental Digital Content, http://links.lww.com/QAI/A680). The total effect of always 
being exposed to abacavir, during the entire four year period, versus never being exposed was HR 
2.06, 95% CI 1.43 to 2.98 (Figure 1, right). Cumulative exposure modelling without inverse probability 
weights gave a similar estimate of this total effect (HR 2.10, 95% CI 1.58 to 2.78; Figure 1, right). 
3.4. Additional analyses 
Estimates of the effect of abacavir were not attenuated when an indicator for chronic kidney disease 
was added to the covariates used to calculate inverse probability of treatment weights. Estimates of 
the effect of abacavir were not attenuated in unplanned analyses of patients not infected through 
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injection drug use and of abacavir naive patients. Cumulative exposure modelling suggested 
exposure to didanosine had early harmful and then later protective effects (Figure 2) while exposure 
to tenofovir had if anything a protective rather than a harmful effect (Figure 3). Results for these 
additional analyses are summarised in Sections 3 to 6 of the Supplemental Digital 
Content(http://links.lww.com/QAI/A680). 
4. Discussion 
Our results suggest that the risk of a CVD event increases as past exposure to abacavir cumulates, but 
only for a limited period. Exposure during the past 6 to 36 months causes the greatest increase in 
risk; both current exposure and exposure more than three years ago cause little additional increase 
in risk. Acute inflammation has been suggested as an explanation for the increase in CVD risk with 
exposure to abacavir, because the risk seemed associated with recent and not past exposure.
1,8
 Our 
results suggest other explanations should be sought because the increase in risk is not immediate 
and it cumulates so that past exposure within the last three years still influences current risk. 
Note that the relative risks presented in Table 2 should not be interpreted too literally. The models in 
this table illustrate how different partitions of time – into current, recent or cumulative use – can 
lead to different clinical conclusions. Our estimated weight function (Figure 1, left) does not require 
this arbitrary partitioning and is therefore a more reliable basis for drawing clinical conclusions. 
Having estimated this weight function, a contrast between any two treatment histories can be 
generated and we show one contrast of obvious interest – the effect of always being exposed to 
abacavir, over a four year period, versus never being exposed (Figure 1, right). 
With our data, we were able to reproduce estimates reported by the D:A:D despite the changes in 
prescribing behaviour brought about by the publication of their results. While the SHCS contributes 
data to the D:A:D, only 45% of our 365 events occurred prior to February 2007 and might therefore 
have been included in their original analysis. The results of our cumulative exposure modelling 
explain seemingly inconsistent results from earlier studies. If the harmful effects of exposure 
cumulate but only for a finite period, and yet patients are exposed to abacavir for much longer, 
cumulative exposure per year will appear weakly harmful at best.
13,35
 Exposure to abacavir more than 
six months earlier may well appear harmful, although studies may lack the power to really confirm or 
rule out such an effect.
1,36
 Recent use should appear harmful, as it has in many studies,
1,14,35,36
 but 
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may underestimate the short term risk if current use is included in the definition of recent use, 
because current use appears protective.
13
 
An early protective effect could arise because abacavir, as part of an effective therapy, reduces viral 
replication, a risk factor for CVD events,
37,38
 or because of a ‘reverse causation bias’ 
39
 if patients at 
high risk of a CVD event were taken off abacavir after only a short exposure but then went on to have 
such an event. Our modelling suggests that after the D:A:D’s results were published, patients with a 
previous CVD event or a high Framingham risk score were taken off abacavir (Section 1, 
Supplemental Digital Content, http://links.lww.com/QAI/A680). But of the 53 high risk patients who 
stopped taking abacavir after February 2008, only two went on to have a CVD event and both had at 
least five year’s exposure to abacavir. 
This change in prescribing behaviour was considered prudent.
9
 However for patients that smoke, 
giving up smoking leads to a greater reduction in CVD risk than avoiding exposure to abacavir.
6,40
 For 
many patients , the increase in relative risk with exposure to abacavir will be acceptable, if other risk 
factors for CVD are absent,
41
 given the low rate of CVD events – 4.6 per 1000 patient-years in these 
data – and that alternatives such as tenofovir also have side-effects.
31,42
 The question of whether – 
and how – abacavir increases the risk of cardiovascular disease is still important.  The recently 
approved co-formulation of dolutegravir, a new integrase inhibitor, with abacavir and lamivudine 
provides a one pill once a day regimen that is likely to prove popular with patients.
43,44
 Integrase 
inhibitors are well-tolerated antiretrovirals because they do not interfere with normal cellular 
processes 
45
 and are therefore considered suitable for patients at risk of cardiovascular disease.
46
 
Strengths of this study include that this is an analysis of data from a single cohort. This avoids the 
additional variation that arises when contributing cohorts in a multi-cohort collaboration use 
different methods to collect and measure data. Our confidence intervals for estimates of effect sizes 
are of a similar width to those reported in the D:A:D’s original study,
1
 yet in our data we have only 
half the number of CVD events (365 versus 693 events). We use modelling that does not require 
strong assumptions about the relationship between exposure and outcome. As a consequence, in our 
results we see a relationship between exposure to abacavir and the risk of CVD events that is both 
plausible – in that risk lags exposure and does not cumulate indefinitely – and explains seemingly 
inconsistent results from earlier studies. Finally, unlike other observational studies, our analyses also 
account for covariates potentially on a causal pathway between exposure to abacavir and CVD; this 
reduces the residual confounding that would otherwise arise when those exposed to abacavir are at 
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greater risk of CVD than the unexposed.
18
 Note that estimates in Table 2 with and without marginal 
structural modelling are similar, vindicating those who maintained that such modelling would not 
have altered the conclusions of their analyses.
1,29,35
 However, marginal structural modelling was 
important in our analysis of tenofovir (Figure 3). 
We note the following study limitations. As in the D:A:D study,
1
 not all patients were abacavir-naïve 
at the start of follow up, with 13% of patients pre-exposed. Those pre-exposed to abacavir had a 
higher prevalence of dyslipidemia and of moderate or high Framingham risk scores (data not shown) 
but our modelling of continued use of abacavir took such factors into account. A causal 
interpretation of our results is only possible if there is no unmeasured confounding.
19
 We did not 
adjust for time dependent injection drug use because routine recording of this only began in July 
2008. Note however that sensitivity analyses of abacavir naive patients and of patients not infected 
through injection drug use gave similar results to the main analysis. We did not have sufficient events 
to warrant cumulative exposure modelling of the risk of myocardial infarction alone (see Table 1). 
The implication of these results is that a rapidly acting mechanism, such as acute inflammation,
1,8
 
may not be responsible for the increased risk of CVD with exposure to abacavir. A possible early 
protective effect and a later cumulative harmful effect suggest more gradual processes. One 
possibility for a cumulative harmful effect is mitochondrial toxicity,
47
 as abacavir may interact with 
cytidine analogues lamivudine and emtricitabine.
48
 The heart, with its high metabolic demand, is rich 
in mitochondria and is susceptible to mitochondrial damage, especially as it ages.
49
 Several 
mechanisms could be involved: equivalent modelling of the risk of CVD with exposure to didanosine 
suggests that the two drugs may affect CVD in different ways. Our results for didanosine suggest an 
unexpected dual effect – a rapid early harmful effect followed by a later protective effect (Figure 2). 
This might explain why other studies show that recent exposure to didanosine is harmful but that 
cumulative exposure has no net effect 
1,35
 or even a protective effect.
36
 In the updated D:A:D analysis, 
plots showing the rate of myocardial infarction with cumulative exposure are consistent with what 
we report here – with abacavir, the rate increases and then levels off after two to three years of 
exposure; with didanosine, the rate seems to peak after about one to two years of exposure and may 
then decline.
35
 
Our results suggest a number of directions for future research. First one could reconsider more 
gradual processes that might give rise to an increasing risk of CVD with cumulating exposure to 
abacavir. Second one could look for evidence of a protective effect with current exposure to abacavir 
in data collected before the D:A:D’s results prompted clinicians to take high risk patients off abacavir. 
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Third one could consider whether the harmful effects of abacavir and didanosine might involve 
substantially different processes. While our analyses suggest that exposure to abacavir increases the 
risk of CVD, they also suggest that acute processes are unlikely to be the cause. 
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Figure 1. The effect of exposure to abacavir on the risk of cardiovascular disease events: the 
estimated weight function (left) and the estimated total cumulative effect (as a hazard ratio) of 
always being treated with abacavir over the past 48 months versus never being treated with abacavir 
(right). Exposure more than four years ago was assumed to have no effect on current risk. Functions 
are shown for cumulative exposure modelling with both marginal structural (solid curve) and 
conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions considered, the 
best fitting weight function had a single knot and (exposure) weights of zero at both the beginning 
and end of the four year interval. 
  
Figure 2. The effect of exposure to didanosine on the risk of cardiovascular disease events: the 
estimated weight function (left) and the estimated total cumulative effect (as a hazard ratio) of 
always being treated with didanosine over the past 30 months versus never being treated with 
didanosine (right). Exposure more than 30 months ago was assumed to have no effect on current 
risk. Functions are shown for cumulative exposure modelling with both marginal structural (solid 
curve) and conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions 
considered, the best fitting weight function had a single knot and (exposure) weights of zero at both 
the beginning and end of the 30 month interval. 
  
Figure 3. The effect of exposure to tenofovir on the risk of cardiovascular disease events: the 
estimated weight function (left) and the estimated total cumulative effect (as a hazard ratio) of 
always being treated with tenofovir over the past 48 months versus never being treated with 
tenofovir (right). Exposure more than four years ago was assumed to have no effect on current risk. 
Functions are shown for cumulative exposure modelling with both marginal structural (solid curve) 
and conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions 
considered, the best fitting weight function had a single knot and (exposure) weights of zero at both 
the beginning and end of the four year interval. 
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Table 1: Characteristics of patients at the time of their first cardiovascular disease event or if no such event, at their last follow up visit – median or proportion. 
Characteristic Patients with a cardiovascular disease event 
 All Exposed to antiretroviral therapy 
a
 
  Exposed to 
abacavir 
Exposed to 
didanosine 
Exposed to 
tenofovir 
Patients 
without a 
cardiovascular 
disease event 
General      
Number of patients 365 195 151 148 11491 
Male 0.83 0.83 0.81 0.83 0.70 
Age (years) 45 44 46 44 35 
CD4 cell count (cells/µL) 470 500 460 460 510 
Suppressed viral load 
b
 0.76 0.80 0.75 0.82 0.76 
Body mass index > 26 kg/m
2
 0.25 0.23 0.22 0.26 0.26 
Current smoker 0.61 0.58 0.59 0.61 0.47 
Ex-smoker 0.21 0.22 0.22 0.25 0.21 
Infected through injection drug 
use 
0.22 0.22 0.24 0.26 0.19 
Cardiovascular disease      
Previous event 
c
 0.14 0.12 0.13 0.12 0.01 
Family history 
d
 0.19 0.16 0.20 0.18 0.11 
Diabetes mellitus 
e
 0.15 0.15 0.15 0.17 0.06 
Chronic kidney disease 
f
 0.21 0.17 0.21 0.11 0.09 
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Hypertension      
Use of anti-hypertensive 
medication 
0.43 0.43 0.36 0.45 0.18 
Arterial hypertension 
g
 0.59 0.61 0.54 0.64 0.34 
Lipid levels      
Total cholesterol (mmol/L) 5.4 5.5 5.6 5.4 4.9 
HDL cholesterol (mmol/L) 1.1 1.1 1.1 1.1 1.2 
Use of lipid lowering 
medication 
0.32 0.32 0.35 0.33 0.10 
Dyslipidemia 
h
 0.65 0.63 0.68 0.62 0.36 
Lipodystrophy 
i
 0.45 0.46 0.54 0.48 0.27 
Framingham risk score 
j
      
Low (<10%) 0.40 0.41 0.42 0.40 0.76 
Moderate (10-20%) 0.45 0.43 0.42 0.47 0.21 
High (>20%) 0.15 0.17 0.15 0.14 0.03 
Cardiovascular disease event 
k
      
Myocardial infarction 0.51 0.56 0.57 0.47 NA 
Invasive cardiovascular 
procedure 
l
 
0.72 0.72 0.72 0.76 NA 
Cardiovascular death 0.12 0.10 0.14 0.08 NA 
Abbreviations: NA, not applicable. 
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a
 Patients could be exposed to none of these three drugs or to one or more. 
b
 HIV RNA undetectable or below 50 copies / mL. 
c
 Cardiovascular disease event before the patients first cardiovascular risk assessment. 
d
 Myocardial infarction or stroke before the age of 50 in any first degree relative. 
e
 Clinical diagnosis, or casual plasma glucose >11.1 mmol/L, or on anti-diabetic medication or insulin. 
f
 Estimated glomerular filtration rate (calculated using CKD-EPI equation 
32
) < 60 ml/min/1.73m
2
 
g
 Systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or on anti-hypertensive 
medication. 
h
 Total cholesterol > 6.2 mmol/L, HDL cholesterol < 0.9 mmol/L, or on lipid-lowering medication. 
i
 Patient and clinician report either body fat loss or body fat gain. 
j
 Estimated risk of cardiovascular disease in the next 10 years. 
k
 More than one event can occur during the same month. 
l
 Coronary angioplasty/stenting, coronary artery by-pass grafting, carotid endarterectomy, 
procedures on other arteries. 
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Table 2. The relative risk of a cardiovascular disease event for patients exposed to abacavir. 
Exposure parameters Conventional model 
a
 Marginal structural model 
b
 
 Hazard ratio (95% CI) Hazard ratio (95% CI) 
Model 1 
c
     
Cumulative exposure (per year) 1.04 (0.99, 1.10) 1.04 (0.97, 1.10) 
Recent exposure within past 0 to 6 months 1.50 (1.12, 2.00) 1.63 (1.14, 2.32) 
     
Model 2 
d
     
Cumulative exposure (per year) 1.05 (1.00, 1.10) 1.05 (0.98, 1.11) 
Recent exposure within past 1 to 6 months 3.69 (2.36, 5.75) 4.61 (2.59, 8.23) 
Current exposure 0.36 (0.23, 0.55) 0.28 (0.15, 0.50) 
     
Model 3 
e
     
Cumulative exposure within the past 7 to 36 
months (per year) 
1.25 (1.04, 1.51) 1.22 (0.98, 1.52) 
Recent exposure within past 1 to 6 months 3.20 (1.97, 5.19) 4.06 (2.24, 7.34) 
Current exposure 0.35 (0.22, 0.54) 0.27 (0.15, 0.50) 
a
 Models adjusted for age, sex, likely transmission through injection drug use, Caucasian ethnicity, family 
history of coronary heart disease, previous CVD event, smoking status, body mass index, calendar year, 
and cumulative exposure to 15 other antiretroviral drugs. 
b
 Models fit using inverse probability weights, with weights found using 8 different logistic regression 
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models. The covariates in these models included those used in the conventional models plus indicators 
for hypertension, dyslipidaemia, diabetes, Framingham risk score categories and continuous measures 
of CD4 cell count and log 10 HIV RNA. 
c
 Model 1 reproduced an analysis reported by the D:A:D - their estimates were HR 1.03, 95% CI 0.96 to 
1.10, per year for cumulative exposure and HR 1.63, 95% CI 1.30 to 2.04, for recent exposure 
1
. 
d
 Model 2 was suggested by cumulative exposure modelling – weight functions where the effect of 
current exposure could have a weight other than zero had negative weights for the earliest months of 
the four year interval suggesting that current exposure had a protective effect. 
e
 Model 3 was suggested by cumulative exposure modelling – the best fitting weight function (Figure 1, 
left)  suggested that cumulating exposure to abacavir over the past 6 to 36 months causes the greatest 
increase in the risk of a CVD event. 
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Figure 1. The effect of exposure to abacavir on the risk of cardiovascular disease events: the estimated weight function (left) and the estimated total 
cumulative effect (as a hazard ratio) of always being treated with abacavir over the past 48 months versus never being treated with abacavir (right). Exposure 
more than four years ago was assumed to have no effect on current risk. Functions are shown for cumulative exposure modelling with both marginal structural 
(solid curve) and conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions considered, the best fitting weight function had a single 
knot and (exposure) weights of zero at both the beginning and end of the four year interval. 
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Figure 2. The effect of exposure to didanosine on the risk of cardiovascular disease events: the estimated weight function (left) and the estimated total 
cumulative effect (as a hazard ratio) of always being treated with didanosine over the past 30 months versus never being treated with didanosine (right). 
Exposure more than 30 months ago was assumed to have no effect on current risk. Functions are shown for cumulative exposure modelling with both marginal 
structural (solid curve) and conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions considered, the best fitting weight function 
had a single knot and (exposure) weights of zero at both the beginning and end of the 30 month interval. 
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Figure 3. The effect of exposure to tenofovir on the risk of cardiovascular disease events: the estimated weight function (left) and the estimated total 
cumulative effect (as a hazard ratio) of always being treated with tenofovir over the past 48 months versus never being treated with tenofovir (right). Exposure 
more than four years ago was assumed to have no effect on current risk. Functions are shown for cumulative exposure modelling with both marginal structural 
(solid curve) and conventional (dashed curve) Cox models.
23,50
 Of the nine alternative weight functions considered, the best fitting weight function had a single 
knot and (exposure) weights of zero at both the beginning and end of the four year interval. 
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